Hongbin Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongbin Liang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Conghui Wang
Genetic and Prenatal Diagnosis Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication - David S. Cram
Genetics and Precision Medicine Center The First People's Hospital of Kunming Kunming China
1 shared publication - Donald A. Leigh
Genetics and Precision Medicine Centre, The First People's Hospital of Kunming, Kunming, Yunnan, China
1 shared publication - Fa-Lin Wang
Department of Clinical Laboratory The Forth Affiliated Hospital of Harbin Medical University Harbin China
1 shared publication - Guohua Ji
Laboratory of Medical Genetics, Harbin Medical University, Harbin,China
1 shared publication - Nan Wang
Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
1 shared publication
Latest Publications
- Open Access
- 29 January 2024
- Published by Elsevier in Genetics in Medicine Open
- Vol. 2, 101816
Next-generation variant exon screening: Moving forward in routine genetic disease investigations
- 29 January 2024
- Published by Elsevier in Genetics in Medicine Open
- Vol. 2, 101816
Open AccessNext-generation variant exon screening: Moving forward in routine genetic disease investigations
- Open Access
- 1 July 2019
- Published by Korean Society for Molecular and Cellular Biology
- Vol. 42 (7) , 557-567
TSPAN12 Precedes Tumor Proliferation by Cell Cycle Control in Ovarian Cancer
TSPAN12, a member of the tetraspanin family, has been highly connected with the pathogenesis of cancer. Its biological function, however, especially in ovarian cancer (OC), has not been well elucidated. In this study, The Cancer Genome Atlas (TCGA) dataset analysis revealed that upregulation of TSPAN12 gene expression was significantly correlated with patient survival, suggesting that TSPAN12 might be a potential prognostic marker for OC. Further exploration showed that TSPAN12 overexpression accelerated proliferation and colony formation of OVCAR3 and SKOV3 OC cells. Knockdown of TSPAN12 expression in A2780 and SKOV3 cells decreased both proliferation and colony formation. Western blot analysis showed that several cyclins and cyclin-dependent kinases (CDK) (e.g., Cyclin A2, Cyclin D1, Cyclin E2, CDK2, and CDK4) were significantly involved in the regulation of cell cycle downstream of TSPAN12. Moreover, TSPAN12 accelerated mitotic progression by controlling cell cycle. Thus, our data demonstrated that TSPAN12 could be a novel molecular target for the treatment of OC.
- 1 July 2019
- Published by Korean Society for Molecular and Cellular Biology
- Vol. 42 (7) , 557-567
Open AccessTSPAN12 Precedes Tumor Proliferation by Cell Cycle Control in Ovarian Cancer
TSPAN12, a member of the tetraspanin family, has been highly connected with the pathogenesis of cancer. Its biological function, however, especially in ovarian cancer (OC), has not been well elucidated. In this study, The Cancer Genome Atlas (TCGA) dataset analysis revealed that upregulation of TSPAN12 gene expression was significantly correlated with patient survival, suggesting that TSPAN12 might be a potential prognostic marker for OC. Further exploration showed that TSPAN12 overexpression accelerated proliferation and colony formation of OVCAR3 and SKOV3 OC cells. Knockdown of TSPAN12 expression in A2780 and SKOV3 cells decreased both proliferation and colony formation. Western blot analysis showed that several cyclins and cyclin-dependent kinases (CDK) (e.g., Cyclin A2, Cyclin D1, Cyclin E2, CDK2, and CDK4) were significantly involved in the regulation of cell cycle downstream of TSPAN12. Moreover, TSPAN12 accelerated mitotic progression by controlling cell cycle. Thus, our data demonstrated that TSPAN12 could be a novel molecular target for the treatment of OC.